Population pharmacokinetic modelling of darifenacin and its hydroxylated metabolite using pooled data, incorporating saturable first-pass metabolism, CYP2D6 genotype and formulation-dependent bioavailability

Population pharmacokinetic modelling of darifenacin and its hydroxylated metabolite using pooled data, incorporating saturable first-pass metabolism, CYP2D6 genotype and formulation-dependent bioavailability

Item

http://www.wikidata.org/entity/Q30884154

Q30884154

about

Assessment of the relative in vivo potency of the hydroxylated metabolite of darifenacin in its ability to decrease salivary flow using pooled population pharmacokinetic-pharmacodynamic data Once-daily trospium chloride 60 mg extended release in subjects with overactive bladder syndrome who use multiple concomitant medications: Post hoc analysis of pooled data from two randomized, placebo-controlled trials.Effects of four different meal types on the population pharmacokinetics of single-dose rifapentine in healthy male volunteers.Population pharmacokinetics of rifapentine and its primary desacetyl metabolite in South African tuberculosis patients.Muscarinic receptors in the bladder: from basic research to therapeutics.Darifenacin: a muscarinic M3-selective receptor antagonist for the treatment of overactive bladder.Population pharmacokinetic analysis for nelfinavir and its metabolite M8 in virologically controlled HIV-infected patients on HAART.Darifenacin: a novel M3 muscarinic selective receptor antagonist for the treatment of overactive bladder.Refractory overactive bladder: a common problem?Overview of model-building strategies in population PK/PD analyses: 2002-2004 literature survey.Treatment of overactive bladder in the aging population: focus on darifenacin.Comparison of model-based tests and selection strategies to detect genetic polymorphisms influencing pharmacokinetic parameters Importance of hematocrit for a tacrolimus target concentration strategy.Darifenacin for the treatment of overactive bladder.Novel biomarkers for overactive bladder.Pharmacokinetics and toxicity of antimuscarinic drugs for overactive bladder treatment in females.Clinical Determinants of Target Non-Attainment of Linezolid in Plasma and Interstitial Space Fluid: A Pooled Population Pharmacokinetic Analysis with Focus on Critically Ill Patients.Development of a sufficient design for estimation of fluconazole pharmacokinetics in people with HIV infection.Population pharmacokinetic analysis of circadian rhythms in hepatic CYP3A activity using midazolam.

P2860

Q30891304-498D7B2E-E569-45B5-B09C-D94241C38A03 Q33806201-9C0FF10C-89CA-4D47-8537-78031AD96D4F Q34045240-1EF79CEF-B303-42A1-BFB2-1CBF4519861E Q34123784-561246EB-9711-40A9-A58D-E81F797B05EC Q34564708-D5F39956-C424-4F5A-873A-86380D126479 Q34575850-3F760763-0854-4D62-A34D-F5E0890B23EE Q35826943-BD75E056-9F46-4C17-A9CA-64D745082451 Q35925590-4ADA4A6E-F876-4DEE-90C4-CB3023579CD7 Q36073640-FDBAC684-D375-4AC1-9CC3-7E8C49236E8B Q36388088-63AB9941-3B4A-4FC8-8D52-E6B044AFA9B0 Q37018934-336A7103-9802-4613-A8AF-A3104674880D Q37441810-A32F5FCE-6EB7-43E3-9880-7E18F1200D8E Q37469289-5F1329F1-887A-48C7-9358-286417BC9AF2 Q37608354-128256CC-5FA6-4035-A8F8-F80B5485AED8 Q37842130-78B3CD89-7E57-458F-9E8C-4EDC529B343F Q38032608-2F4111C4-FC77-4062-B44A-1332AAD3217F Q39278957-2AC09D69-79F0-4278-9C54-FE8C3181E549 Q43112879-50C6E1EF-D877-4976-B6EE-7B37CE74CD75 Q47877276-83E87D3F-59BA-4F46-80FD-EF2EA0E6013D

P2860

Population pharmacokinetic modelling of darifenacin and its hydroxylated metabolite using pooled data, incorporating saturable first-pass metabolism, CYP2D6 genotype and formulation-dependent bioavailability

Item

http://www.wikidata.org/entity/Q30884154

description

2003 nî lūn-bûn

@nan

2003 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2003 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2003年の論文

@ja

2003年論文

@yue

2003年論文

@zh-hant

2003年論文

@zh-hk

2003年論文

@zh-mo

2003年論文

@zh-tw

2003年论文

@wuu